Estimating the starting dose for entry into humans: principles and practice.
about
A simple practice guide for dose conversion between animals and humanChanges in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob miceTo scale or not to scale: the principles of dose extrapolationEvaluation of the cohort size in phase I dose escalation trials based on laboratory data.Applications of human pharmacokinetic prediction in first-in-human dose estimationOn the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.Interspecies scaling of therapeutic monoclonal antibodies: initial look.Prediction of drug clearance in children 3 months and younger: an allometric approach.Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling.Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Physiologically based pharmacokinetic (PBPK) modeling in children.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data.Assessing the therapeutic use of Lafoensia pacari St. Hil. extract (mangava-brava) in the eradication of Helicobacter pylori: double-blind randomized clinical trial.Metabolic and Blood Pressure Effects of Walnut Supplementation in a Mouse Model of the Metabolic Syndrome.Mitigating effect of Indian propolis against mitomycin C induced bone marrow toxicity.Hypercholesterolemia and Ecto-enzymes of Purinergic System: Effects of Paullinia cupana.In vivo protective effect of Copaifera langsdorffii hydroalcoholic extract on micronuclei induction by doxorubicin.Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach.Pretreatment with quercetin prevents changes in lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in hyperlipidemic rats.Effects of Fish and Grape Seed Oils as Core of Haloperidol-Loaded Nanocapsules on Oral Dyskinesia in Rats.An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
P2860
Q26750843-54121917-1AEB-489E-816B-3681A2D5F9B4Q28476015-9280F6AA-5B60-414D-B665-636C75DBC10DQ28751735-C7503156-24B0-4CC7-9EFA-F0519A21ACC4Q30794443-D96BEF86-75EF-4E8E-B8AE-E1ACDE3A6CEDQ35888391-77E812DA-CB2D-4FED-8C70-5B37BF4A46F5Q36985094-6F2ED579-A33E-4C7A-A18A-6D95E367E7EBQ37161497-D8B78534-D222-47D6-879A-DB8D6FBF8028Q37535669-5FF06CE9-EBD5-4514-A009-AE9D38331406Q37570459-1D1F1B05-1216-4384-A055-102EB1DB5556Q37616947-E9CEE769-54E0-4EDA-AF88-9E21EB858FDBQ37854677-75A41B01-1137-460E-880D-0106B3D479FBQ37964570-D989D88C-8705-491E-A8D7-2221EFE13C45Q37976121-1A8F96E5-5BE5-47D2-9508-6C7E78F97239Q38016332-A80E75F4-61E7-40BA-BB51-B17342B782BDQ38121644-207AACCC-5F78-4A9E-A7A1-80C484F03C77Q38627882-ABC9D711-F759-4A09-897A-A1600FEDA71CQ38690068-AC7C3077-D59A-4FF4-8B05-B0031896E2E5Q39351550-D01EEEAC-9C3A-4987-8C4D-1B659B3D40CAQ41195251-7694F6E0-E4D4-456F-B546-E647B9C2BDF2Q41639686-BA06ABAE-C003-4F8F-B017-6130817146D1Q42484364-6D80A60B-EF14-413F-AF75-D4A1B4C59398Q44261630-D03B83B3-B7C3-4550-9496-C73B5F50A730Q46492814-87543F5D-B256-419D-8D19-75CFD222DF52Q49501602-602D3E53-7AD3-445A-A631-06016CE42CDCQ50055276-FE29C027-F4AD-4959-9A4A-A11117D67B24Q50593562-BB4ABB8D-6ED2-4445-AAE2-82AFACCEFD7B
P2860
Estimating the starting dose for entry into humans: principles and practice.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Estimating the starting dose for entry into humans: principles and practice.
@en
Estimating the starting dose for entry into humans: principles and practice.
@nl
type
label
Estimating the starting dose for entry into humans: principles and practice.
@en
Estimating the starting dose for entry into humans: principles and practice.
@nl
prefLabel
Estimating the starting dose for entry into humans: principles and practice.
@en
Estimating the starting dose for entry into humans: principles and practice.
@nl
P1476
Estimating the starting dose for entry into humans: principles and practice.
@en
P2093
Bruno G Reigner
Karen Smith Blesch
P2888
P304
P356
10.1007/S00228-001-0405-6
P577
2002-02-01T00:00:00Z
P6179
1039840212